Journal Home Online First Current Issue Archive For Authors Journal Information 中文版

2010, Volume 4, Issue 1

Abstract

Keywords

Related Research

Back to Top

Frontiers of Medicine >> 2010, Volume 4, Issue 1 doi: 10.1007/s11684-010-0010-0

Mitogen-activated protein kinase pathway inhibitors: inhibitors for diseases?

1.College of Life Science, Northeast Forestry University, Harbin 150040, China；Key Laboratory of Functional Proteomics of Guangdong Province, Department of Pathophysiology, Southern Medical University, Guangzhou 510515, China; 2.Key Laboratory of Functional Proteomics of Guangdong Province, Department of Pathophysiology, Southern Medical University, Guangzhou 510515, China; 3.College of Life Science, Northeast Forestry University, Harbin 150040, China;

Available online: 2010-03-05
HTML11 PDF 4 Collect 0

Next Previous

Abstract

Mitogen-activated protein kinase (MAPK) signaling pathway, one of the most important signaling pathways in eukaryotic organism, is involved in multiple cellular events such as cell growth, differentiation, and apoptosis. MAPK is of great importance to the normal function of organisms, while its dysfunction results in various diseases. So far, inhibitors specifically against each subfamilies of MAP kinase have been developed, while more endeavors are needed to discover the compounds selectively targeting a particular subfamily member. Most of the kinase inhibitors exert their functions in an ATP-competitive way or a non-ATP-competitive way. Further studies on the effective mechanism of the MAPK inhibitors and their therapeutic roles in the treatment of diseases are helpful for the illumination of MAP kinase function, the development of novel inhibitors, and the therapy of diseases caused by the dysfunction of the MAPK pathway.

Related Research